Final Overall Survival, Other Efficacy and Safety Results from ASCEND-3: Phase II Study of Ceritinib in ALKi-Naïve Patients With ALK-Rearranged Non-Small-Cell Lung Cancer.
The phase II, single-arm ASCEND-3 study assessed efficacy and safety of ceritinib in anaplastic lymphoma kinase (ALK) inhibitor (ALKi)-naïve patients with ALK-rearranged non-small-cell lung cancer (NSCLC) who had received ≤ 3 prior lines of chemotherapy. Here, we report the final efficacy and safety results. Eligible patients (including those with asymptomatic or neurologically stable brain metastases [BM]) received oral ceritinib 750 mg/day (fasted). Primary endpoint: investigator-assessed overall response rate (ORR). Secondary endpoints: Blinded Independent Review Committee (BIRC)-assessed ORR; investigator- and BIRC-assessed overall intracranial response rate, duration of response (DOR), time to response, disease control rate, and progression-free survival (PFS); overall survival (OS); and safety. Exploratory endpoints: patient-reported outcomes. Of the 124 patients enrolled, 122 (98.4%) had received prior antineoplastic medications (31 patients [25.0%], ≥ 3 regimens), and 49 (39.5%) had baseline BM. Median follow-up time (data cutoff: January 22, 2018): 52.1 months (range, 48.4-60.1). Investigator-assessed ORR was 67.7% (95% CI, 58.8 to 75.9) and median PFS was 16.6 months (95% CI, 11.0 to 23.2). Median OS was 51.3 months (95% CI, 42.7 to 55.3). Most common adverse events (AEs [all grades], ≥ 60% of patients, all-causality): diarrhea (85.5%), nausea (78.2%), and vomiting (71.8%). Overall, 18 patients (14.5%) had an AE leading to treatment discontinuation. Health-related quality of life was maintained during ceritinib treatment. Ceritinib demonstrated prolonged and clinically meaningful OS, PFS, and DOR in chemotherapy pretreated (≤ 3 lines), ALKi-naïve patients with ALK+ NSCLC. The safety profile is consistent with that of previously reported studies.